Terrie Curran is President, Chief Executive Officer & Director at Phathom Pharmaceuticals, Inc. Ms. Curran is also on the board of Myovant Sciences Ltd., Roivant Sciences, Inc. and Arcutis Biotherapeutics, Inc.

Ms. Curran previously occupied the position of SVP & GM-Global Women's Health at Merck & Co., Inc. and General Manager for Schering-Plough Corp. (a subsidiary of Merck & Co., Inc.) and President-Global Inflammation & Immunology at Celgene Corp.

Terrie Curran received an undergraduate degree from the University of Technology Sydney.